Role of cholecystokinin in the development of BOP-induced pancreatic lesions in hamsters.

Abstract

Cholecystokinin (CCK) has been shown to promote pancreatic growth and azaserine-induced pancreatic carcinogenesis in rats. The present study was carried out to determine effects of CCK on pancreatic growth and carcinogenesis in the N-nitrosobis(2-oxopropyl)amine (BOP) hamster model. One hundred male Syrian golden hamsters were injected s.c. once weekly with 20 mg BOP/kg body wt at 6, 7 and 8 weeks of age, and divided into four groups of 25 animals each, which received one of the following treatments (once daily, 3 days/week for 16 weeks): gelatin; CR-1409, a potent CCK-receptor antagonist; CCK-8, 2.5 micrograms/kg body wt; or CCK-8 in combination with CR-1409 (30 min before CCK treatment). The animals were killed after 19 weeks. The growth of the pancreas but not the incidence of pancreatic (pre)neoplastic lesions was enhanced by CCK-8. CR-1409 did not influence the effect of CCK on pancreatic growth.

• Authors: M Meijers, A van Garderen-Hoetmer, C B Lamers, L C Rovati, J B Jansen, R A Woutersen
• Journal: Carcinogenesis (Carcinogenesis) Vol. 11 Issue 12 Pg. 2223-6 (Dec 1990) ISSN: 0143-3334 [Print] England
• PMID: 2265473 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Carcinogens
• Nitrosamines
• nitrosobis(2-oxopropyl)amine
• Cholecystokinin
• Proglumide
• lorglumide

Topics

• Animals
• Body Weight (drug effects)
• Carcinogens
• Cholecystokinin (adverse effects, pharmacokinetics)
• Cocarcinogenesis
• Cricetinae
• Male
• Nitrosamines
• Organ Size (drug effects)
• Pancreas (drug effects)
• Pancreatic Neoplasms (chemically induced)
• Proglumide (analogs & derivatives, pharmacology)